Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Rheumatoid Arthritis
•
General Rheumatology
•
JAK Inhibitors
•
Gastroenterology
•
Cirrhosis
•
Hepatology
Do you avoid JAK inhibitors in patients with a history of liver disease including NAFLD or cirrhosis?
Related Questions
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
Have you utilized JAK inhibitors in patients on dialysis?
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
Does the presence of calcified granulomas on chest imaging influence your choice of biologic for treatment of psoriatic arthritis (or rheumatoid arthritis)?
Do you have any experience with compounded iguratimod either as adjunctive therapy or monotherapy for rheumatoid arthritis, Sjogrens, or axial spondyloarthropathy?
In a patient with a history of seropositive erosive RA who has undergone treatment for a periprosthetic joint infection and currently has an antibiotic spacer in place with clinical improvement, what is the appropriate timing and strategy for restarting DMARDs and/or biologic therapy to balance infection risk with RA disease control?
What is your approach to differentiating RA-ILD from medication toxicity (I.e. from methotrexate)?
What is your approach to choosing a particular advanced therapy based on patient or disease factors when initiating treatment for moderate-severe IBD?
Can Xolair (omalizumab) be safely used in combination with biologics for patients with rheumatic disease?
When trying to increase infliximab for active disease (inflammatory arthritis or sarcoidosis), do you prefer to increase dosage or reduce frequency between doses?
